The Committee for Medicinal Products for Human Use (CHMP) has told Pharmaxis (ASX:PXS) it can’t market its Bronchitol drug in Europe, because the benefit of the drug hasn’t been established.
Pharmaxis said it a statement to the ASX today that it doesn’t agree with the committee’s refusal, and wants it to re-examine the marketing application.
The pharmaceutical company’s CEO Alan Robertson says the drug addresses an urgent need for drugs to restore and repair the airway surface in the lung. The drug is to be used for the treatment of cystic fibrosis.
For the second half of last year, Pharmaxis (ASX:PXS) reported a loss of $22.3 million.
